NasdaqGS:IBRXBiotechs
Is Chemo‑Free NK Regimen and Global ANKTIVA Push Altering The Investment Case For ImmunityBio (IBRX)?
ImmunityBio recently announced the ResQ215B Phase 2 trial, testing a chemotherapy-free, lymphodepletion-free CD19-targeted NK-cell, ANKTIVA, and rituximab regimen in indolent B‑cell non-Hodgkin lymphoma, while also securing expanded approvals and planned launches for ANKTIVA in multiple international markets.
This combination of off-the-shelf cellular therapy with an IL-15 superagonist highlights ImmunityBio’s attempt to differentiate immuno-oncology treatments from conventional CAR-T...